NCT00685399 - Safety and Efficacy of AIN457 in Noninfectious Uveitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Non-infectious Uveitis

Interventions

DRUG

AIN457

AIN457 subcutaneous dose

DRUG

AIN 457

AIN457 low dose (i.v)

DRUG

AIN457

AIN457 high dose (i.v)

Trial Locations (23)

10022

Novartis Investigative Site, New York

12159

Novartis Investigative Site, Slingerlands

13353

Novartis Investigative Site, Berlin

21201

Novartis Investigative Site, Baltimore

21287

Novartis Investigative Site, Baltimore

27710

Novartis Investigative Site, Durham

29306

Novartis Investigative Site, Spartanburg

30322

Novartis Investigative Site, Atlanta

44195

Novartis Investigative Site, Cleveland

64111

Novartis Investigative Site, Kansas City

72076

Novartis Investigative Site, Tübingen

76012

Novartis Investigative Site, Arlington

77030

Novartis Investigative Site, Houston

78793

Novartis Investigative Site, Austin

80120

Novartis Investigative Site, Littleton

80210

Novartis Investigative Site, Denver

80401

Novartis Investigative Site, Golden

90033

Novartis Investigative Site, Los Angeles

90211

Novartis Investigative Site, Beverly Hills

95819

Novartis Investigative Site, Sacramento

691120

Novartis Investigative Site, Heidelberg

02142

Novartis Investigative Site, Cambridge

07666

Novartis Investigative Site, Teaneck